This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
Zogenix Inc
ZGNX : NASDAQ : Health Care
$1.37 0.03 | 2.24%
Today's Range: 1.31 - 1.37
Avg. Daily Volume: 3,769,600
03/30/15 - 4:00 PM ET

Financial Analysis


ZOGENIX INC's gross profit margin for the fourth quarter of its fiscal year 2014 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ZOGENIX INC has average liquidity. Currently, the Quick Ratio is 1.35 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 200.00% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY14 Q4 FY13
Net Sales ($mil)14.99.92
EBITDA ($mil)0.0-14.1
EBIT ($mil)-27.06-14.51
Net Income ($mil)-20.52-35.62


Balance Sheet Q4 FY14 Q4 FY13
Cash & Equiv. ($mil)50.7172.02
Total Assets ($mil)202.84112.5
Total Debt ($mil)23.1528.8
Equity ($mil)55.2818.43


Profitability Q4 FY14 Q4 FY13
Gross Profit Margin-22.6329.17
EBITDA Margin0.0-142.14
Operating Margin-181.64-146.29
Sales Turnover0.20.29
Return on Assets4.23-71.86
Return on Equity15.53-438.81
Debt Q4 FY14 Q4 FY13
Current Ratio1.761.58
Debt/Capital0.30.61
Interest Expense0.091.82
Interest Coverage-297.38-8.0


Share Data Q4 FY14 Q4 FY13
Shares outstanding (mil)141.05138.93
Div / share0.00.0
EPS-0.14-0.28
Book value / share0.390.13
Institutional Own % n/a n/a
Avg Daily Volume3719869.01966780.0

Valuation


SELL. ZOGENIX INC's P/E ratio indicates a significant premium compared to an average of 31.65 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 19.41. Conducting a second comparison, its price-to-book ratio of 3.34 indicates a premium versus the S&P 500 average of 2.74 and a significant discount versus the industry average of 8.05. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ZGNX 65.50 Peers 31.65   ZGNX NA Peers 49.24

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ZGNX is trading at a significant premium to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ZGNX NM Peers 17.70   ZGNX NM Peers 1.13

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ZGNX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ZGNX's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ZGNX 3.34 Peers 8.05   ZGNX 102.77 Peers 32.33

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ZGNX is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ZGNX is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ZGNX 4.56 Peers 7.15   ZGNX 22.77 Peers 12.73

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ZGNX is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ZGNX has a sales growth rate that significantly exceeds its peers.

 

 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Latest Stock Upgrades/Downgrades


Top Rated Stocks Top Rated Funds Top Rated ETFs